Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates

Rapid, quantitative, and objective determination of the susceptibilities of human cytomegalovirus (HCMV) clinical isolates to ganciclovir has been assessed by an assay that uses a fluorochrome-labeled monoclonal antibody to an HCMV immediate-early antigen and flow cytometry. Analysis of the ganciclovir susceptibilities of 25 phenotypically characterized clinical isolates by Bow cytometry demonstrated that the 50% inhibitory concentrations (IC(50)s) of ganciclovir for 19 of the isolates were between 1.14 and 6.66 mu M, with a mean of 4,32 mu M (+/-1.93) (sensitive; IC50 less than 7 mu M), the IC(50)s for 2 isolates were 8.48 and 9.79 mu M (partially resistant), and the IC(50)s for 3 isolates were greater than 96 mu M (resistant). Comparative analysis of the drug susceptibilities of these clinical isolates by the plaque reduction assay gave IC(50)s of less than 6 mu M, with a mean of 2.88 mu M (+/-1.40) for the 19 drug-sensitive isolates, IC(50)s of 6 to 8 mu M for the partially resistant isolates, and IC(50)s of greater than 12 mu M for the four resistant clinical isolates. Comparison of the IC(50)s for the drug-susceptible and partially resistant clinical isolates obtained by the flow cytometry assay with the IC(50)s obtained by the plaque reduction assay showed an acceptable correlation (r(2) = 0.473; P = 0.001), suggesting that the Bow cytometry assay could substitute for the more labor-intensive, subjective, and time-consuming plaque reduction assay.